Log in to save to my catalogue

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessme...

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessme...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811907761

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

About this item

Full title

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

Publisher

United States: Elsevier Inc

Journal title

The American heart journal, 2016-06, Vol.176, p.83-92

Language

English

Formats

Publication information

Publisher

United States: Elsevier Inc

More information

Scope and Contents

Contents

Background Statin-mediated low-density lipoprotein cholesterol (LDL-C) lowering fails to prevent more than half of cardiovascular events in clinical trials. Serial plaque imaging studies have highlighted the benefits of aggressive LDL-C lowering, with plaque regression evident in up to two-thirds of patients with achieved LDL-C levels <70 mg/dL. Pr...

Alternative Titles

Full title

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1811907761

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811907761

Other Identifiers

ISSN

0002-8703

E-ISSN

1097-6744

DOI

10.1016/j.ahj.2016.01.019

How to access this item